Macroaxis Stories

Does Aldeyra Therapeutics has strong basic indicators based on the current rise?

July 25, 2020  By Ellen Johnson
Macroaxis Story
In spite of fairly unfluctuating basic indicators, Aldeyra Therapeutics may actually be approaching a critical reversion point that can send shares even higher in August 2020. This firm current probability of distress is over 62%. Are the firm investors still optimistic?
Published over a year ago
View all stories for Aldeyra | View All Stories

Reviewed by Gabriel Shpitalnik

Aldeyra Therapeutics holds a performance score of 17 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.5436, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Aldeyra's beta means in this case. As returns on the market increase, Aldeyra Therapeutics returns are expected to increase less than the market. However, during the bear market, the loss on holding Aldeyra Therapeutics will be expected to be smaller as well. Although it is essential to pay attention to Aldeyra Therapeutics historical returns, it is also good to be reasonable about what you can do with equity current trending patterns. Our philosophy in foreseeing future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Aldeyra Therapeutics expected return of 1.74 will be sustainable into the future, we have found twenty-seven different technical indicators, which can help you to check if the expected returns are sustainable. Use Aldeyra Therapeutics maximum drawdown, and the relationship between the information ratio and expected short fall to analyze future returns on Aldeyra Therapeutics.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Aldeyra income statement, its balance sheet, and the statement of cash flows. Potential Aldeyra investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Aldeyra investors may use each financial statement separately, they are all related. The changes in Aldeyra's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Aldeyra's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Aldeyra fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Aldeyra performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Aldeyra shares is the value that is considered the true value of the share. If the intrinsic value of Aldeyra is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Aldeyra. Please read more on our fundamental analysis page.

How effective is Aldeyra in utilizing its assets?

Aldeyra reports assets on its Balance Sheet. It represents the amount of Aldeyra resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Aldeyra aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect Aldeyra volatility, please check the breakdown of all its fundamentals.

Are Aldeyra Earnings Expected to grow?

The future earnings power of Aldeyra involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Aldeyra factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Aldeyra stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Aldeyra expected earnings.

Aldeyra Gross Profit

Aldeyra Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Aldeyra previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Aldeyra Gross Profit growth over the last 10 years. Please check Aldeyra's gross profit and other fundamental indicators for more details.

Is Aldeyra valued reasonably by the market?

There are few distinct groups of Aldeyra Therapeutics stakehholders that the SEC considers insiders. Investors usually gain information through their work as corporate directors, officers, or employees. If these individuals share the information with a friend, family, or business partner and the person who receives the information exchanges stock in the company, he or shie is also an insider. Let's take a look at how the ownership of Aldeyra is distributed among investors.

Ownership Allocation

Aldeyra Therapeutics retains a total of 34.37 Million outstanding shares. Over half of Aldeyra Therapeutics outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Aldeyra Therapeutics. Please watch out for any change in the institutional holdings of Aldeyra Therapeutics as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Retail Investors
30.12%
Institutions
65.87%
Retail Investors30.12
Insiders4.01
Institutions65.87

Asset Utilization

One of the ways to look at asset utilization of Aldeyra is to check how much profit was generated for every dollar of assets it reports. Aldeyra Therapeutics shows a negative utilization of assets of -45.74 percent, losing $0.4574 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Aldeyra Therapeutics shows how unproductive it operates for each dollar spent on its assets.
Current Assets
62.7 M
Current Assets62.65 Million99.5
Assets Non Current312,3790.5

Our perspective of the current Aldeyra Therapeutics rise

Aldeyra Therapeutics current market risk adjusted performance rises over 3.11. Aldeyra Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Aldeyra Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Aldeyra Therapeutics volatility.

Our Conclusion on Aldeyra Therapeutics

While some other companies within the biotechnology industry are still a little expensive, even after the recent corrections, Aldeyra Therapeutics may offer a potential longer-term growth to investors. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither pick up new shares of Aldeyra nor sell your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Aldeyra Therapeutics.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Aldeyra. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com